Psoriasis patients are at increased risk of atherosclerosis, characterized by endothelial dysfunction, linked through systemic inflammation. Anti-TNF-a therapy seems to decrease this risk. The purpose of this study was to measure the levels of serum markers associated with systemic inflammation in psoriasis patients, compared to healthy individuals and to investigate the change in their levels after 3 months and 2 years of adalimumab therapy. We investigated four biomarkers: high-sensitivity C-reactive protein (hsCRP), oxidized low-density lipoproteins (OxLDL), E-selectin, and Interleukin 22 (IL-22). These markers were measured in healthy volunteers and in 28 patients with moderate/severe psoriasis before and after 3 and 24 months of treatment with adalimumab. Psoriasis patients had increased levels of markers in comparison to the control group. After 3 months of therapy, E-selectin decreased significantly (P < .001), as well as IL-22 (P < .001). hsCRP also decreased but did not show a statistical significance, OxLDL were slightly higher than initially. After 24 months, 17 patients were still being treated with adalimumab. In these patients, hsCRP (P < .05), E-selectin (P < .001) and IL-22 (P < .001) were significantly decreased. OxLDL remained at a higher level. The stable decrease of E-selectin, hsCRP, and IL-22 after 24 months confirms that adalimumab suppresses systemic inflammation.

3rd Faculty of Medicine 2nd Department of Internal Medicine Charles University and Kralovske Vinohrady University Hospital Prague Czech Republic

3rd Faculty of Medicine Department of Dermatology and Venereology Charles University and Kralovske Vinohrady University Hospital Prague Czech Republic

Zobrazit více v PubMed

Jung KJ, Kim TG, Lee JW, et al. Increased risk of atherosclerotic cardiovascular disease among patients with psoriasis in Korea: a 15-year nationwide population-based cohort study. J Dermatol. 2019;46(10):859-866.

Davidovici BB, Sattar N, Prinz J, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010;130:1785-1796.

Boehncke W-H. Systemic inflammation and cardiovascular comorbidity in psoriasis patients: causes and consequences. Front Immunol. 2018;9:579.

Karadag AS, Yavuz B, Ertugrul DT, et al. Is psoriasis a pre-atherosclerotic disease? Increased insulin resistance and impaired endothelial function in patients with psoriasis. Int J Dermatol. 2010;49:642-646.

Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2010;31:1000-1006.

Patel N, Nadkarni A, Cardwell LA, et al. Psoriasis, depression, and inflammatory overlap: a review. Am J Clin Dermatol. 2017;18:613-662.

Gisondi P, Fostini AC, Fossà I, Girolomoni G, Targher G. Psoriasis and the metabolic syndrome. Clin Dermatol. 2018;36:21-28.

Boehncke WH, Boehncke S, Tobin AM, Kirby B. The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011;20:303-307.

Awad SM, Attallah DA, Salama RH, Mahran AM, Abu El-Hamed E. Serum levels of psoriasin (S100A7) and koebnerisin (S100A15) as potential markers of atherosclerosis in patients with psoriasis. Clin Exp Dermatol. 2018;43:262-267.

Robati RM, Partovi-Kia M, Sadat-Amini H, Haghighatkhah HR, Younespour S, Toossi P. Serum osteopontin level and common carotid artery intima-media wall thickness in psoriasis. Int J Dermatol. 2016;55:e262-e267.

Gkalpakiotis S, Arenbergerova M, Gkalpakioti P, Potockova J, Arenberger P, Kraml P. Impact of adalimumab treatment on cardiovascular risk biomarkers in psoriasis: results of a pilot study. J Dermatol. 2017;44:363-369.

Genre F, Armesto S, Corrales A, et al. Significant sE-selectin levels reduction after 6 months of anti-TNF therapy in non-diabetic patients with moderate-to-severe psoriasis. J Dermatolog Treat. 2017;28:726-730.

Takahashi H, Tsuji H, Hashimoto Y, Ishida-Yamamoto A, Iizuka H. Serum cytokines and growth factor levels in Japanese patients with psoriasis. Clin Exp Dermatol. 2010;35:645-649.

Gerdes S, Osadtschy S, Buhles N, Baurecht H, Mrowietz U. Cardiovascular biomarkers in patients with psoriasis. Exp Dermatol. 2014;23:322-325.

Jókai H, Szakonyi J, Kontár O, et al. Impact of effective tumor necrosis factor-alfa inhibitor treatment on arterial intimal-media thickness in psoriasis: results of a pilot study. J Am Acad Dermal. 2013;69:523-529.

Mäki-Petäjä KM, Elkhawad M, Cheriyan J, et al. Anti-tumor necrosis factor-α therapy reduces aortic inflammation and stiffness in patients with rheumatoid arthritis. Circulation. 2012;126:2473-2480.

Mäki-Petäjä KM, Elkhawad M, Cheriyan J, et al. Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study. J Eur Acad Dermatol Venereol. 2011;25:1187-1193.

Raaby L, Ahlehoff O, de Thurah A. Psoriasis and cardiovascular events: updating the evidence. Arch Dermatol Res. 2017;309:225-228.

Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation. 2006;113:1888-1904.

Pina T, Genre F, Lopez-Mejias R, et al. Asymmetric dimethylarginine but not osteoprotegerin correlates with disease severity in patients with moderate-to-severe psoriasis undergoing anti-tumor necrosis factor: a therapy. J Dermatol. 2016;43:389-394.

Martin JC, Wolk K, Bériou G, et al. Limited presence of IL-22 binding protein, a natural IL-22 inhibitor, strengthens psoriatic skin inflammation. J Immunol. 2017;198:3671-3678.

Shi L, Ji Q, Liu L, et al. IL-22 produced by Th22 cells aggravates atherosclerosis development in ApoE−/− mice by enhancing DC-induced Th17 cell proliferation. J Cell Mol Med. 2020;24:3064-3078.

Malik I, Danesh J, Whincup P, et al. Soluble adhesion molecules and prediction of coronary heart disease: a prospective study and meta-analysis. Lancet. 2001;358:971-976.

Hope SA, Meredith IT. Cellular adhesion molecules and cardiovascular disease. Part II. Their association with conventional and emerging risk factors, acute coronary events and cardiovascular risk prediction. Intern Med J. 2003;33:450-462.

Pirillo A, Norata GD, Catapano AL. LOX-1, OxLDL, and atherosclerosis. Mediators Inflamm. 2013;2013:152786.

Tekin NS, Tekin IO, Barut F, Sipahi EY. Accumulation of oxidized low-density lipoprotein in psoriatic skin and changes of plasma lipid levels in psoriatic patients. Mediators Inflamm. 2007;2007:78454.

Masztalewicz M, Nowacki P, Kotlęga D, Bajer-Czajkowska A, Drechsler H. Anti-oxLDL antibodies are clinically insignificant for stroke patients. Neurol Res. 2014;36:86-91.

Khambhati J, Engels M, Allard-Ratick M, Sandesara PB, Quyyumi AA, Sperling L. Immunotherapy for the prevention of atherosclerotic cardiovascular disease: promise and possibilities. Atherosclerosis. 2018;276:1-9.

Liu H, Yao Y, Wang Y, et al. Association between high-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2 and carotid atherosclerosis: a cross-sectional study. J Cell Mol Med. 2018;22:5145-5150.

Gelfand JM, Shin DB, Duffin KC, et al. A randomized placebo controlled trial of Secukinumab on aortic vascular inflammation in moderate to severe plaque psoriasis (VIP-S). J Invest Dermatol. 2020. [Epub ahead of print]. https://doi.org/10.1016/j.jid.2020.01.025.